XML 41 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Mar. 21, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Registrant Name Omega Therapeutics, Inc.    
Entity Central Index Key 0001850838    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Common Stock, Shares Outstanding   55,154,985  
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Title of 12(b) Security Common stock, par value $0.001 per share    
Trading Symbol OMGA    
Security Exchange Name NASDAQ    
Entity File Number 001-40657    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 81-3247585    
Entity Address, Address Line One 140 First StreetSuite 501    
Entity Address, City or Town Cambridge    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02141    
City Area Code 617    
Local Phone Number 949-4360    
Document Transition Report false    
ICFR Auditor Attestation Flag false    
Entity Public Float     $ 140.2
Document Financial Statement Error Correction [Flag] false    
Documents Incorporated by Reference [Text Block]

Portions of the Registrant’s definitive proxy statement relating to its 2024 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2023, are incorporated herein by reference in Part III.

    
Auditor Name Deloitte & Touche LLP    
Auditor Firm ID 34    
Auditor Location Boston, Massachusetts